Company intelligence / Profile preview
Pan-Biome Pharmaceuticals, Inc.
Vancouver, British Columbia, Canadapan-biomepharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has reported positive results in preclinical trials for colitis. Their lead compound activates anti-inflammatory cytokine IL-10 and inhibits pro-inflammatory cytokines TNF-a, IL-1b, and IL-6. It also activates NRF2 and AMPK expression, which are important in delaying aging. The compound has shown to extend lifespan in C. elegans by 30% and modulates the gut microbiome, increasing beneficial bacteria like Akkermansia muciniphila[3][5][6].
- Therapeutic areas
- OtherGastroenterologyImmunology
- Modalities
- Small moleculesnatural product-based compounds
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Pan-Biome Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pan-Biome Pharmaceuticals, Inc..